1. Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib.
- Author
-
Funck-Brentano T, Cohen-Solal M, Ducray F, and Mandonnet E
- Subjects
- Humans, Male, Chondroma diagnostic imaging, Chondroma drug therapy, Chondroma pathology, Adult, Radiography, Isocitrate Dehydrogenase genetics, Isocitrate Dehydrogenase antagonists & inhibitors, Mutation genetics, Pyridines therapeutic use, Enchondromatosis diagnostic imaging, Enchondromatosis drug therapy, Enchondromatosis pathology, Enchondromatosis genetics, Glycine analogs & derivatives, Glycine therapeutic use
- Abstract
Ollier Disease (OD) and Maffucci syndrome (MS) is a rare bone disorder that affects the growth and development of the bones, with an estimated prevalence of 1 in 100,000 people. It is associated with somatic mosaicism of isocitrate dehydrogenase-1 (IDH1) or 2 (IDH2) pathogenic variants. Ivosidenib is indicated for the treatment of acute myeloid leukemia and locally advanced or metastatic cholangiocarcinoma and is currently investigated in low-grade glioma with a susceptible isocitrate dehydrogenase-1 (IDH1) pathogenic variant, but its effects in patients with OD or MS are unknown. We here report the first case of a patient with MS who was treated with Ivosidenib for recurrent IDH-1 mutated glioma. Besides the stabilization of the tumor size, the patient observed significant improvement in his enchondromas that became stiffer, with reduced pain, and significant modification of the mineralization of the enchondromas observed on X-rays. This first case report provides hope for the medical management of patients suffering because of OD or MS. Future clinical research is urgently needed to evaluate long-term benefit risk profile of IDH inhibitors in these rare diseases., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF